Canaccord Genuity Reiterates a 'Buy' on Protalix BioTherapeutics (PLX); Expect Tali Data at WORLD to Back Approval, Clean Label
Tweet Send to a Friend
Canaccord Genuity reiterates a 'Buy' on Protalix BioTherapeutics (NYSE: PLX), PT $13.
Canaccord analyst says, "We think PLX/partner Pfizer’s (NYSE ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "We think PLX/partner Pfizer’s (NYSE ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
